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Abstract
Background: M-CSF recruits mononuclear phagocytes which regulate processes such as angiogenesis and metastases in
tumors. VEGF is a potent activator of angiogenesis as it promotes endothelial cell proliferation and new blood vessel
formation. Previously, we reported that in vitro M-CSF induces the expression of biologically-active VEGF from human
monocytes.
Methodology and Results: In this study, we demonstrate the molecular mechanism of M-CSF-induced VEGF production.
Using a construct containing the VEGF promoter linked to a luciferase reporter, we found that a mutation reducing HIF
binding to the VEGF promoter had no significant effect on luciferase production induced by M-CSF stimulation. Further
analysis revealed that M-CSF induced VEGF through the MAPK/ERK signaling pathway via the transcription factor, Sp1. Thus,
inhibition of either ERK or Sp1 suppressed M-CSF-induced VEGF at the mRNA and protein level. M-CSF also induced the
nuclear localization of Sp1, which was blocked by ERK inhibition. Finally, mutating the Sp1 binding sites within the VEGF
promoter or inhibiting ERK decreased VEGF promoter activity in M-CSF-treated human monocytes. To evaluate the
biological significance of M-CSF induced VEGF production, we used an in vivo angiogenesis model to illustrate the ability of
M-CSF to recruit mononuclear phagocytes, increase VEGF levels, and enhance angiogenesis. Importantly, the addition of a
neutralizing VEGF antibody abolished M-CSF-induced blood vessel formation.
Conclusion: These data delineate an ERK- and Sp1-dependent mechanism of M-CSF induced VEGF production and
demonstrate for the first time the ability of M-CSF to induce angiogenesis via VEGF in vivo.
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Introduction
Macrophage-Colony Stimulating Factor (M-CSF) acts on
mononuclear phagocytes, stimulating proliferation, driving differ-
entiation of monocytes to macrophages, and protecting these cells
against apoptosis [1–3]. Many cell types, including fibroblasts [4],
monocytes [5], endothelial cells [6] and tumor cells [7] secrete M-
CSF. M-CSF recruits mononuclear phagocytes to sites of injury or
inflammation by itself [8] or through a paracrine loop involving
monocyte chemoattractant protein-1 (CCL2/MCP-1) [9]. Upon
binding M-CSF, the M-CSF receptor dimerizes and elicits
intrinsic tyrosine kinase activity triggering signaling pathways that
induce cell survival. Using human monocytes, we previously
demonstrated that M-CSF activates the phosphatidylinositol 3-
kinase/Akt (PI3K/Akt) pathway, which induces cell survival by
suppressing caspase-9 and caspase-3 activation [1]. Also, M-CSF
activates the pro-survival mitogen-activated protein kinase
(MAPK) pathway, including ERK, p38, and JNK [10–13].
VEGF is a potent activator of angiogenesis as it promotes
endothelial cell proliferation and new blood vessel formation [14].
During hypoxic conditions, the Hypoxia-Inducible Factor (HIF)
proteins regulate VEGF production. At low oxygen levels, the HIFs
are stabilized and bind promoter sites known as hypoxia regulatory
elements (HREs), driving the transcription of over 20 hypoxia-
inducible genes [15]. During normoxia, VEGF can be expressed
from cells by hypoxia-independent mechanisms still involving the
HIF apparatus. For example, ERK can phosphorylate and activate
HIF-1a thereby increasing VEGF expression [16]. Alternatively,
VEGF can be expressed in a HIF-independent fashion. In cancer
cells lines, Akt activation through Sp1 increases VEGF expression
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upstream regulator of the MEK/ERK pathway) can induce VEGF
expression in hamster fibroblast cells [18].
M-CSF, mononuclear phagocytes, and VEGF are linked to
poor prognosis in patients with solid tumors. For example, M-CSF
is elevated in breast cancer patients with advanced disease and
distant metastases compared to patients with localized tumors
[19,20]. In addition, a higher peripheral blood monocyte count is
related to tumor progression and is an independent risk factor for
recurrence of hepatocellular carcinoma after resection [21].
Finally, the importance of VEGF in tumor progression is well-
established. In breast and lung cancer patients, VEGF expression
negatively correlates with relapse-free and overall survival [22,23].
Additionally, a monoclonal antibody against VEGF, Bevacizu-
mab, inhibits tumor growth by blocking angiogenesis and is
approved for use with chemotherapy to treat metastatic colon
cancer [24] and metastatic non-small cell lung cancer [25].
Because of the critical effects of angiogenesis and VEGF on tumor
growth and metastases and the clear negative prognostic role of
M-CSF and VEGF in human tumors, we sought to define the
biochemical mechanisms underlying M-CSF-induced VEGF
production. This approach extends our previous observations that
M-CSF directly induces functional VEGF production from human
monocytes [26].
Here, we decipher the molecular mechanism of M-CSF-
induced VEGF production. Further, we illustrate the in vivo ability
of M-CSF to induce VEGF production and cause subsequent
angiogenesis.
Material and Methods
Purification of peripheral blood monocytes
Single donor human monocytes were isolated from leukocyte
source packs obtained from the American Red Cross (Columbus,
OH) as described previously [27].
Inhibitor studies
Human monocytes (10610
6 cells/condition) were left untreat-
ed, treated with DMSO or methanol, the MEK/ERK inhibitor,
U0126 (10 mM), the JNK inhibitor, SP600125 (10 mM), the p38
MAP kinase inhibitor, SB203580 (10 mM), the PI3K/Akt
inhibitor, LY294002 (1 mMo r1 0 mM), the mTOR inhibitor,
Rapamycin (0.1, 1, or 10 mM), or mithramycin (8, 40, and
200 nM) for 30 minutes (Calbiochem, San Diego, CA). After-
wards, the cells were stimulated with rhM-CSF (100 ng/ml) for
48 hours and the cell-free supernatants were frozen until assayed
for VEGF by ELISA (R&D Systems, Minneapolis, MN).
Western blot analysis
Protein was harvested using Cell Lysis Buffer from Cell
Signaling. Whole cells lysates were standardized using the Bio-
Rad Protein Assay Kit. Western blots were performed using
NuPAGEH 10% Bis-Tris gels, NuPAGEH MOPS SDS Running
Buffer, and NuPAGEH Transfer Buffer (Invitrogen) and subse-
quently transferred to nitrocellulose paper and probed with the
following antibodies: phosphorylated p44/p42 MAPK (Thr202/
Tyr204) (#9101L, Cell Signaling) and equal loading was observed
by blotting for total ERK2 (sc-154, Santa Cruz).
Sp1 Transcription Factor Binding Assay
Human monocytes were either left non-stimulated or stimulated
with rhM-CSF (100 ng/ml) for 30 minutes. Nuclear lysates were
isolated from the cells using the CelLytic
TM NuCLEAR
TM
Extraction Kit (Sigma). All samples were normalized for total
protein using the Bio-Rad Protein Assay Kit. The amount of Sp1
in the nuclear lysates was analyzed using the NoShift
TM
Transcription Factor Assay Kit and NoShift
TM Sp1 reagents as
described by the manufacturer (Novagen).
Confocal microscopy
Human monocytes were left non-stimulated or stimulated with
rhM-CSF (100 ng/ml) for 6 or 24 hours. Cells were fixed then
permeablized with 1% Triton X-100 and subsequently blocked
with 5% goat serum in PBS, incubated overnight with 1 mg/ml of
either a primary antibody to human Sp1 (Upstate) or IgG control
antibody (Santa Cruz). The cells were incubated with a 1:5000
dilution of Alexa 594-conjugated secondary antibody (Molecular
Probes). The slides were then viewed and imaged using the Zeiss
LSM 510 confocal microscope. Images were quantified using
Image J software. Cells were differentiated from debris by using
the phase contrast photos and only those cells displaying monocyte
morphology, horseshoe-shaped nuclei, were included in the
analysis.
VEGF promoter analysis
All luciferase reporter constructs containing both wild type and
mutant sequences based on the VEGF promoter were supplied by
Dr. Amit Maity (University of Pennsylvania). 1 mg of each
construct was transfected into freshly-isolated human monocytes
using the Amaxa Nucleofector Transfection System as per the
manufacturer’s protocol (Amaxa). All cells were incubated in
100 ng/ml rhM-CSF for 16 hours, lysed using Promega Lysis
Buffer on ice, and centrifuged to remove cell debris. 20 ml of each
cell lysate was mixed with 90 ml luciferase substrate and read on
the luminometer in triplicate.
VEGF mRNA analysis
Monocyte total RNA was collected using the Absolutely
RNA
TM RT-PCR Miniprep Kit StratageneH (La Jolla, CA) for
total RNA purification as previously described [26]. cDNA was
synthesized using the Gibco BRL SuperScript First-Strand
Synthesis System for RT-PCR Kit. Real-time polymerase chain
reaction was performed using the human VEGF forward primer
(59-AGGCCAGCACATAGGAGAGATG-39), and reverse primer
(59-CAAGGCCCACAGGGATTTTC-39). The primers for
VEGF mRNA were designed based on the human VEGF-A
sequence obtained from PubMed (Genbank accession
no. NM003376). Reaction conditions were as follows: 10 ml
SYBRH Green PCR Master Mix (Applied Biosystems), 0.4 ml
each forward and reverse VEGF primers (10 mM) or primers
targeting GAPDH (control), 8.2 ml RNase-free water, and 1.0 ml
cDNA (0.5 mg) for a total reaction of 20 ml. The real-time PCR
was completed on the ABI PRISM Sequence Detector 7700
(PerkinElmer) using Sequence Detector software. Reaction
conditions were as follows: 50uC for 2 min, 95uC for 10 min,
and 40 cycles of 95uC for 15 s and 60uC for 1 min. Quantification
was performed as previously described [28].
In vivo Matrigel
TM plug assay
C57BL/6 female mice purchased from Jackson Laboratories
(Bar Harbor, ME) were anesthetized with isoflurane and
subcutaneously injected with 0.5 ml growth factor-reduced
Matrigel
TM matrix (Discovery Labware, Bedford, MA) supple-
mented with either PBS, rmVEGF (10 ng/ml), rmM-CSF
(100 ng/ml), rmM-CSF (100 ng/ml)+anti-VEGF neutralizing
antibody (5 mg/ml), or rmM-CSF (100 ng/ml)+isotype IgG
antibody (5 mg/ml). All components added to the unpolymerized
MCSF-Induced VEGF by Monocytes
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TM were allowed to incubate at 4uC for at least 12 hours
prior to injection. After 10 days, the mice were sacrificed and the
Matrigel
TM plugs removed, formalin-fixed, paraffin-embedded
and sectioned.
Immunohistochemistry
Mononuclear phagocyte recruitment within the plugs was
identified using an anti-F4/80 antibody (Serotec, MCAP497).
VEGF was detected within the plugs by staining with a rabbit anti-
VEGF antibody or the isotype IgG antibody (LabVision, RM-
9128-R7). Endothelial cell infiltration into the plugs was
determined by an anti-von Willebrand factor (vWf) antibody
(Abcam, ab6994). Blood vessels within each plug are defined as
complete circles of vWf(+)-stained cells. All staining was performed
at the Pathology Core at The Ohio State University.
Statistical analyses
Statistics were determined by The Ohio State University
Medical Center for Biostatistics. For IHC of F4/80(+) cells and
VEGF and the Sp1 binding assay, an independent samples
Student’s T-Test was used to assess differences between groups.
An ANOVA with Tukey’s post-hoc test was performed to
determine differences between groups in the blood vessel counts,
ELISA studies, confocal microscopy data and the VEGF promoter
constructs data. For the inhibitor studies and the luciferase assays,
difference in fold change over treatment was tested using a
random-intercept mixed model. Fold change was log transformed
for variance stabilization and a single overall p-value that tests if
there is a difference between treatments was generated. All
analyses were run on Stata 10.0, Stata Corporation, College
Station, Texas. Groups were considered significantly different at
p,0.05.
Results
M-CSF-induced VEGF production from monocytes occurs
through a HIF-independent mechanism
We demonstrated M-CSF induces the production and release of
biologically active VEGF from human monocytes [26]. Here, we
elucidate the biochemical mechanism of this phenomenon by first
investigating the role of the hypoxia-inducible factors (HIFs).
During hypoxic stress, HIFs are the master regulators of VEGF
and function by binding to the hypoxia regulatory element (HRE)
sequence within the VEGF promoter. We utilized both wild type
and mutant VEGF promoter constructs driving luciferase
production. We transfected human monocytes with either the
pGL3-basic empty vector, the same pGL3 construct containing a
1.5 kb portion of the wild type VEGF promoter, or a VEGF
promoter construct containing a mutated HRE to prohibit HIF
protein binding (Figure 1A). This assay measures luciferase
production as a function of VEGF promoter activation. All cells
were transfected using the Amaxa Nucleofector, stimulated with
M-CSF, and subsequent luciferase production was measured at
16 hours and represented as fold-change over the luciferase
production from the pGL3 empty vector. When transfecting the
eGFP control construct into human monocytes, we observed an
efficiency of 55.3% as analyzed by flow cytometry (data not
shown). Cells expressing the VEGF wild type construct displayed a
4.5-fold increase in luciferase production compared to the pGL3-
basic empty vector control (p=0.020). Mutation in the HRE did
not affect the luciferase production (p=0.743) suggesting M-CSF-
induced VEGF promoter activation is HIF-independent
(Figure 1B).
Figure1.M-CSFinduced VEGF productionoccursthrougha HIF-
independent mechanism. A) The 1.5 kb wild type VEGF promoter
(WT1.5 kb) andthesamepromoter sequencecontaininga non-functional
mutation of the hypoxia regulatory element (HRE) (DHRE) were inserted
into the pGL3-basic vector to create constructs that produce luciferase
upon VEGF promoter activation. Nucleotides changed from the original
wild type sequence are designated in bold. Human monocytes were
transfectedwith eitherthecontrol empty construct (pGL3-Basic),or pGL3
containing 1 mg of each of the described VEGF promoter constructs
above. B) Transfected monocytes containing (WT1.5 kb) or (DHRE) were
allowed to adhere for 1 hour in RPMI/5% FBS followed by the addition of
fresh media containing rhM-CSF (100 ng/ml) for 16 hours. The adherent
cells were lysed and assayed for luciferase production using a
luminometer. This data represents the mean+/2SEM of six individual
blood donors. All data is representedas the fold changein luciferase over
the pGL3 control construct.
doi:10.1371/journal.pone.0003405.g001
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PLoS ONE | www.plosone.org 3 October 2008 | Volume 3 | Issue 10 | e3405Figure 2. M-CSF-induced VEGF production from human monocytes is blocked by ERK inhibition and mithramycin. A) Monocytes
were pre-incubated with DMSO (vehicle control), 1 mMo r1 0mM the PI3 kinase inhibitor (LY294002) for 30 minutes. The monocytes were either left
non-stimulated (NS), stimulated with rhM-CSF (100 ng/ml) (M-CSF), with rhM-CSF (100 ng/ml) plus DMSO (M-CSF+DMSO), or rhM-CSF (100 ng/ml)
plus 1 or 10 mM LY294002 (1) and (10) for 48 hours. Cell-free supernatants were evaluated for VEGF by ELISA. These data represent the mean6SEM
from four independent donors. B) Monocytes were pre-incubated with DMSO (vehicle control) or 10 mM of the inhibitor of ERK activity (U0126) for
30 minutes. The monocytes were either left non-stimulated (NS), stimulated with rhM-CSF (100 ng/ml) plus DMSO (M-CSF+DMSO) or with rhM-CSF
(100 ng/ml) plus U0126 (M-CSF+U0126 (10 mM)) for 48 hours. Cell-free supernatants were evaluated for VEGF by ELISA. These data represent the
mean6SEM from six independent donors. C) Freshly-isolated human monocytes were plated overnight in 5% FBS and M-CSF (20 ng/ml). The next
day the cells were starved for 2 hours in minimal media. For the last 30 minutes, DMSO (vehicle control) or 10 mM U0126 was added to the
MCSF-Induced VEGF by Monocytes
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production
M-CSF activates both the PI3 kinase/Akt pathway [1] and MAP
kinase pathway, including ERK [29], p38 [30], and JNK [31]. Both
over-expression of Akt and activation of ERK can drive VEGF
production in cancer cell lines or in hamster fibroblasts, respectively
[32,33]. Therefore, we investigated the roles of Akt and the MAP
kinases in M-CSF-induced VEGF production from primary human
monocytes. We treated peripheral blood monocytes with pharma-
cological inhibitors targeting PI3 kinase, the upstream activator of
Akt (LY294002), mTOR, a signaling molecule downstream of Akt
(Rapamycin), JNK (SP600125), p38 (SB203580), or ERK (U0126)
and stimulated these cells with M-CSF. We analyzed VEGF levels
in the supernatants by ELISA. Our data suggested that the PI3-K/
Akt pathway did not regulate M-CSF-induced VEGF production as
neither LY294002 nor Rapamycin affected VEGF production
(p=0.898 for 1 mM and p=0.334 for 10 mM LY294002)
(Figure 2A) and (p=1.0 for 1 mM and p=0.640 for 10 mM
Rapamycin) (data not shown). Importantly, the inhibition of ERK
activity by U0126 reduced VEGF production from M-CSF-
stimulated monocytes to that produced from non-stimulated cells
(p,0.001) (Figure 2B). Western blot analysis confirmed that M-
CSF induced ERK1/2 phosphorylation, which was inhibited by
U0126 (Figure 2C). Our data also indicated that M-CSF-induced
VEGF was not regulated by either p38 or JNK as inhibitors
targeting these pathways did not affect M-CSF-induced VEGF
production (p=0.44 and p=0.62, respectively) (data not shown).
Cell viability in response to all inhibitors was analyzed by Trypan
blue exclusion and was not adversely affected (data not shown).
Mithramycin inhibits VEGF production
Sp1 and AP-2 are transcription factors phosphorylated and
activated by ERK [34] and depicted as regulators of VEGF [35].
To investigate the regulatory role of Sp1 or AP-2 in M-CSF-
induced VEGF production, we cultured human monocytes and
pre-treated with methanol (vehicle control) or mithramycin, an
inhibitor that intercalates into GC-rich regions of DNA and
inhibits the binding of transcription factors like Sp1 and AP-2.
Monocytes were left untreated or treated with M-CSF for
48 hours and VEGF levels in the supernatants were analyzed by
ELISA. Mithramycin (40 nM and 200 nM) significantly inhibited
M-CSF-induced VEGF production compared to vehicle-treated
cells (p,0.05, respectively) (Figure 2D). Cell viability as assessed
by Trypan Blue exclusion was not affected in cells treated with
mithramycin up to 200 nM (data not shown).
To verify whether the inhibitory effect of mithramycin was due
to inhibition of Sp1 binding, we attempted to use siRNA against
Sp1. Stealth
TM RNAi targeting Sp1 was transfected into primary
human monocytes using Lipofectamine and assayed for a
reduction in total Sp1 protein by Western blot. We found that
protein levels of Sp1 were not depleted from these cells until
48 hours after transfection. This created a challenge in VEGF
determination as cultured, primary human monocytes differentiate
into macrophages which become less responsive to M-CSF and
therefore make it difficult to measure VEGF production from
these cells. Additionally, transfection of monocytes with Lipofec-
tamine alone induced the production of VEGF that masked
induction of VEGF by M-CSF (data not shown). As a result, we
attempted to transfect the siRNA using the Amaxa Nucleofector.
Using this method, transfection alone induced the production of
the soluble form of VEGFR-1, which sequesters VEGF from
antigenic detection by ELISA. For these reasons, we chose to
perform multiple techniques described below to verify the role of
Sp1 in M-CSF-induced VEGF production from these cells.
Sp1 is a downstream activator in M-CSF-induced VEGF
production
The activation of Sp1 during M-CSF stimulation has not been
previously reported. To confirm that M-CSF induces Sp1
activation, we performed an Sp1 binding assay to measure levels
of Sp1 translocation to the nucleus in monocytes stimulated with
M-CSF for 30 minutes. Our results indicate that M-CSF increased
the amount of Sp1 that migrated to the nucleus of human
monocytes (p=0.008) (Figure 3A).
To investigate the role of Erk in Sp1 nuclear translocation, we
analyzed localization of Sp1 in human monocytes by confocal
microscopy. Monocytes were pre-incubated with DMSO (vehicle
control) or U0126 and left untreated or treated with M-CSF for 6
or 24 hours. The cells were fixed and stained using a fluorescently-
conjugated anti-Sp1 antibody and DAPI to stain the nucleus
(Figure 3B). Image J software analysis confirmed that M-CSF
enhanced Sp1 nuclear localization compared to untreated
monocytes (p,0.001). Furthermore, the ERK inhibitor, U0126,
blocked Sp1 nuclear translocation compared to cells treated with
M-CSF plus the vehicle control (DMSO) (p,0.001) (Figure 3C).
M-CSF up-regulates VEGF mRNA transcription in an ERK-
and Sp1-dependent manner
Next, we examined the role of Erk and Sp1 in the
transcriptional regulation of VEGF mRNA. We isolated total
RNA from monocytes left untreated or treated with M-CSF. Using
Real-Time PCR, we found a significant increase in VEGF mRNA
at 6 hours of M-CSF stimulation compared to the untreated
sample (p=0.008) (Figure 4A). Next, we isolated RNA from cells
pre-incubated with U1026, mithramycin, or vehicle controls and
treated with M-CSF. Real-time PCR analysis revealed that
inhibiting the activity of ERK (U0126) (Figure 4B) or Sp1
(mithramycin) (Figure 4C) significantly decreased VEGF mRNA
transcription (p=0.037 and p=0.017, respectively). These data
further supports our hypothesis that M-CSF-induced VEGF
production is transcriptionally regulated and is dependent on
both ERK and Sp1 activity.
ERK and Sp1 are essential for M-CSF to functionally
regulate the VEGF promoter
To investigate the functional role of ERK and Sp1, we
transfected primary human monocytes with wild type or mutant
VEGF promoter constructs that drive luciferase production when
activated. The VEGF wild type promoter region (+54 to 288); the
identical region of the VEGF promoter with the two Sp1 regions
appropriate samples. The cells were left non-stimulated (NS), stimulated with rhM-CSF (100 ng/ml) (M-CSF+DMSO) or (M-CSF+U0126) for 10 minutes.
Cell lysates were probed for phospho-ERK MAP Kinase (Thr202) and total ERK MAP Kinase by western blot analysis. This data is representative of two
independent monocyte donors. D) Monocytes were pre-incubated with methanol (vehicle control) or 8, 40, or 200 nM of the Sp1 transcription factor
binding inhibitor, mithramycin, for 45 minutes. The cells were either left non-stimulated (NS) or stimulated with rhM-CSF (100 ng/ml) (M-CSF), (M-
CSF+MeOH), (M-CSF plus 8 nM, 40 nM, or 200 nM mithramycin) for 48 hours. Cell-free supernatants were evaluated for VEGF by ELISA. These data
represent the mean6SEM from ten independent blood donors.
doi:10.1371/journal.pone.0003405.g002
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PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3405Figure 3. M-CSF induces Sp1 nuclear localization in an ERK-dependent manner. A) Human monocytes were left non-stimulated (NS) or
stimulated with rhM-CSF (100 ng/ml) (M-CSF) for 30 minutes. Nuclear lysates were isolated and normalized for total protein. Sp1 that translocated
into the nucleus in response to M-CSF was analyzed using a biotinylated Sp1 DNA sequence bound to a streptavidin-coated plate, a polyclonal rabbit
anti-Sp1 primary antibody, a HRP-conjugated goat anti-rabbit IgG secondary antibody, and TMB substrate. The absorbance was read at 450 nm to
reflect Sp1 within the nucleus. These data represent the mean6SEM from four independent blood donors. B) Human monocytes were starved for
6 hours, inhibited for 30 minutes with U0126 (10 mM) or DMSO (vehicle control) and left non-stimulated (Non-stimulated) or treated with rhM-CSF for
6 hours (M-CSF+DMSO) and (M-CSF+U0126). The cells were fixed, permeablized, and stained with a normal IgG control antibody (top row) or a primary
MCSF-Induced VEGF by Monocytes
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GC to AA in both instances resulting in no Sp1 binding; an AP-2
mutant (280 to 273) by changing the GG at 275 and 276 to
TA; and an Sp1/AP-2 double mutant were spliced into the pGL3-
basic vector to create the promoter constructs (Figure 5A). To
interrogate the role of ERK in the functional activity of the VEGF
promoter, we transfected monocytes with the VEGF wild type
construct and inhibited ERK activity with U0126 treatment. After
16 hours of M-CSF stimulation, cells transfected with the VEGF
wild type construct produced 10-fold more luciferase than the
pGL3 control vector. Inhibition of ERK activation by U0126
caused a statistically significant reduction in luciferase production
from M-CSF-stimulated cells compared to the cells challenged
with M-CSF plus vehicle control (p,0.001) (Figure 5B).
Next, the VEGF mutant constructs were utilized to investigate
the role of AP-2 in this system and to confirm the biological
activity of Sp1 in response to M-CSF. Again, M-CSF induced a
significant 10-fold increase in luciferase production from mono-
cytes transfected with the VEGF wild type construct compared to
cells transfected with the control pGL3 empty vector (p,0.001).
Monocytes transfected with the Sp1 mutant or the Sp1/AP-2
double mutant produced levels of luciferase similar to cells
transfected with the empty vector and significantly less than the
cells transfected with the VEGF wild type construct (p,0.001 for
both) (Figure 5C). Furthermore, the role of AP-2 in this system
was minimal, as there was not a statistically significant reduction in
luciferase produced by cells transfected with the AP-2 mutant
construct compared to the wild type construct (p=0.105). These
data solidify our hypothesis that M-CSF induces VEGF produc-
tion through the MAPK/ERK pathway via Sp1.
M-CSF promotes mononuclear phagocyte recruitment,
induces VEGF production, and enhances angiogenesis in
vivo
With the molecular mechanism of M-CSF-induced VEGF
production established, we next investigated the in vivo role of
VEGF induced by M-CSF. We performed an in vivo angiogenesis
assay by mixing PBS, VEGF or M-CSF with Matrigel
TM and
subcutaneously injected the solution into the flanks of C57Bl/6
female mice. After 10 days, the plugs were removed and fixed for
analysis by immunohistochemistry. First, we confirmed the ability
of M-CSF to recruit mononuclear phagocytes by staining the PBS-
and M-CSF-containing plugs with an antibody specific for F4/80,
a marker of mononuclear phagocytes (Figure 6A). Significantly
more F4/80(+) cells were present in the M-CSF-treated plugs
compared to those plugs treated with PBS (p=0.046) (Figure 6B).
Next, we stained plugs containing PBS, VEGF (positive control),
or M-CSF with an antibody for murine VEGF to investigate if the
presence of M-CSF in the Matrigel plug augmented VEGF levels.
antibody targeting Sp1 followed by subsequent staining with Alexa 594-conjugated secondary antibody, targeting Sp1 (red), and with DAPI stain
designating the nucleus (blue). Images were captured using the Zeiss LSM 510 confocal microscope. These pictures are representative of four
individual monocyte donors. C) Quantification of Sp1 localization to the nucleus of monocytes (horseshoe-shaped nuclei) using Image J software.
This data represents mean+/2SEM of cells from four individual trials.
doi:10.1371/journal.pone.0003405.g003
Figure 4. M-CSF regulates VEGF mRNA transcription through ERK and Sp1. A) Freshly isolated human monocytes were cultured overnight
in 5% FBS and subsequently starved for 2 hours in minimal media. The cells were stimulated with 100 ng/ml rhM-CSF for 6 hours followed by
isolation of RNA. cDNA was synthesized from total cellular RNA, standardized, and subjected to SYBR Green real-time PCR using primers specific for
VEGF-A. The data represents the mean+/2SEM of six individual donors. B) Freshly isolated human monocytes were cultured overnight in 5% FBS and
subsequently starved for 2 hrs followed by pre-treatment with either DMSO (vehicle control) or U0126 (10 mM) in minimal media for 30 minutes. The
cells were then stimulated with 100 ng/ml rhM-CSF (M-CSF), (M-CSF+DMSO), (M-CSF+U0126 10 mM) and analyzed as stated in A. The data represents
the mean+/2SEM of three individual donors. C) Freshly isolated human monocytes were cultured overnight in 5% FBS and subsequently starved for
2 hours followed by pre-treatment with either methanol (vehicle control) or mithramycin (200 nM) in minimal media. The cells were then stimulated
with 100 ng/ml rhM-CSF (M-CSF), (M-CSF+MeOH), (M-CSF+Mith (200 nM)) and analyzed as in A. The data represents the mean+/2SEM of four
individual donors.
doi:10.1371/journal.pone.0003405.g004
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PLoS ONE | www.plosone.org 8 October 2008 | Volume 3 | Issue 10 | e3405Figure 6. M-CSF induces mononuclear phagocyte recruitment in vivo.A )Matrigel
TM was resuspended with PBS (PBS) or rmM-CSF (100 ng/
ml) (M-CSF) at 4uC overnight and then injected subcutaneously into mice. Matrigel
TM was left in situ for 10 days and then harvested. The plugs were
stained for mononuclear phagocytes using an anti-mouse F4/80 antibody. Brown staining represents F4/80(+) cells within the plug. Pictures shown
were taken using a dissecting microscope (1.56objective lens) (left) to display overall mononuclear phagocyte influx between conditions as well as
an inverted microscope (206objective lens) (right) to show detailed staining of these cells. B) The percent of F4/80(+) cells (brown stain) per plug was
evaluated from 15 digital images captured randomly in a blinded manner. Adobe Photoshop histogram pixel analysis of the brown stain was used for
quantification. This data represents three plugs per group.
doi:10.1371/journal.pone.0003405.g006
Figure 5. ERK and Sp1 are necessary for M-CSF induced functional activation of the VEGF promoter. A) The wild type VEGF promoter
(region 288 to +54 relative to the transcription start site (0)) (288/+54 WT) and the same promoter sequence containing mutations of Sp1 (DSp1), AP-
2( DAP-2), and a Sp1/AP-2 double mutant (DSp1/DAP-2) were inserted into the pGL3-basic vector to drive luciferase production upon VEGF promoter
activation. Nucleotides changed in the mutated sequences are designated in bold. B) Transfected monocytes containing the pGL3 control vector or
(288/+54 WT) were allowed to adhere for 1 hour in RPMI/5% FBS followed by the addition of 10 mM U0126 (288/+54 WT+U0126) for 30 minutes. The
cells were washed and fresh media containing rhM-CSF (100 ng/ml) was added for 16 hours, when the cells were lysed and assayed for luciferase
production using a luminometer. This data represents the mean+/2SD of six individual blood donors. C) Transfected monocytes containing (288/
+54 WT), (DSp1), (DAP-2),o r(DSp1/DAP-2) were allowed to adhere for 1 hour in RPMI/5% FBS followed by the addition of fresh media containing rhM-
CSF (100 ng/ml). After 16 hours, adherent cells were lysed and assayed for luciferase production using a luminometer. This data represents the
mean+/2SD of three individual blood donors.
doi:10.1371/journal.pone.0003405.g005
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PLoS ONE | www.plosone.org 9 October 2008 | Volume 3 | Issue 10 | e3405Figure 7. M-CSF induces VEGF and regulates angiogenesis in vivo.A )Matrigel
TM was resuspended with PBS (PBS), rmVEGF (10 ng/ml) (VEGF)
or rmM-CSF (100 ng/ml) (M-CSF). The slides were stained with either an anti-mouse VEGF antibody or its isotype IgG. Brown staining represents VEGF
within the plug. Pictures were taken using a 206objective lens. B) The amount of brown stain (VEGF) within the plugs was determined by taking 15
digital images randomly using a 206 objective lens in a blinded manner. Quantification of VEGF within each plug was determined by Adobe
Photoshop histogram pixel analysis of the brown stain. C) Matrigel
TM was resuspended with PBS (PBS), rmVEGF (10 ng/ml) (VEGF), rmM-CSF (100 ng/
ml) (M-CSF), or rmM-CSF (100 ng/ml)+anti-VEGF neutralizing antibody (5 mg/ml) (M-CSF+anti-VEGF neutralizing Ab). The plugs were stained for
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PLoS ONE | www.plosone.org 10 October 2008 | Volume 3 | Issue 10 | e3405Qualitatively, more VEGF was present in the M-CSF plugs
compared to the PBS plugs. Additionally, the control stains
demonstrate the specificity of the VEGF antibody as staining with
IgG isotype antibody produced no positive areas (Figure 7A).
Quantitatively, M-CSF significantly elevated the amount of VEGF
(brown stain) in the plugs compared to those plugs with PBS
(p=0.026) (Figure 7B).
To investigate the angiogenic potential of VEGF produced by
M-CSF within these plugs, we mixed PBS, VEGF, M-CSF, M-
CSF plus an anti-VEGF neutralizing antibody, or M-CSF plus an
isotype IgG antibody into Matrigel
TM and injected into the flanks
of mice. We analyzed blood vessel formation in the plugs by
staining for von Willebrand factor (vWf), a glycoprotein present in
blood plasma and produced by endothelial cells, and counted the
number of vWf-positive cells lining blood vessel lumens (com-
pletely-lined circles) throughout the plug (Figure 7C). We found
significant increases in blood vessels in plugs containing either
VEGF or M-CSF compared to plugs containing PBS (p=0.042
and p=0.006, respectively). Furthermore, the number of blood
vessels in plugs containing M-CSF plus a VEGF neutralizing
antibody were significantly less than M-CSF-containing plugs and
no different than PBS-containing plugs (p=0.009 and p=0.970,
respectively) (Figure 7D). We observed no difference in blood
vessel presence between plugs containing M-CSF and plugs
containing M-CSF plus an isotype antibody (data not shown).
These data solidify M-CSF-induced recruitment of mononuclear
phagocytes and production of VEGF as an angiogenesis-inducing
phenomenon.
Discussion
We previously reported that human monocytes produce
biologically-active VEGF in response to M-CSF stimulation [26].
This observation has been subsequently confirmed by Varney et al
[36]. Here, we first investigated the molecular mechanisms involved
in M-CSF-induced VEGF production from human monocytes. We
provide data to support the hypothesis that M-CSF-induced VEGF
production from human monocytes is mediated by ERK activation
leading to the activation of Sp1. We found activated Sp1
translocated to the nucleus, binds to and induces VEGF promoter
activation and results in VEGF production. Additionally, we found
no role of the hypoxia inducible factors (HIFs) in this mechanism.
Furthermore, for the first time, we demonstrate the angiogenic
activity of M-CSF in vivo and illustrate that VEGF is the key
molecule causing M-CSF-induced angiogenesis.
M-CSF can activate multiple cell signaling pathways that lead to
VEGF production. For example, in murine cardiomyocytes, M-
CSF functions through Akt to produce VEGF in response to
ischemic injury, improving cardiac function [37]. Also, M-CSF
activates the MAP kinases which play roles in VEGF production as
ERK activation enhances VEGF promoter activity and p38 and
JNK stabilize VEGF mRNA [34]. Using pharmacological
inhibitors of PI3 kinase and mTOR, a downstream molecule in
the Akt pathway, we found no role for the PI3 kinase/Akt pathway
in M-CSF-induced VEGF production. Also, inhibition of p38 or
JNK did not affect M-CSF induced VEGF production in human
monocytes. However, it is possible that p38 and JNK can
functionally compensate for each other as they have been shown
to have the same mechanism of increasing VEGF levels by
stabilizing VEGF mRNA [38].
The VEGF promoter contains binding sites for the transcription
factors Sp1, AP-2 and the HIFs. Interestingly, ERK can induce
the direct phosphorylation of both HIF-1a and Sp1 [16,39]. The
HIFs are known as the master regulators of VEGF and are
responsible for the production of VEGF in response to hypoxia.
However, HIFs can also induce VEGF production in non-hypoxic
environments in response to cytokines and growth factors [40].
Varney et al demonstrated enhanced levels of HIF-1a after
72 hours of M-CSF stimulation and showed M-CSF-induced
binding to the HRE by EMSA, suggesting a HIF-dependent
mechanism [36]. However, when we mutated the HRE within the
VEGF promoter, we did not observe any reduction in the levels of
VEGF promoter activity in response to M-CSF. M-CSF may
affect the stability of the HIFs and induce their binding to the
HRE, but we did not observe a functional role for HIF binding in
M-CSF-induced VEGF promoter activity.
The transcription factor Sp1 is activated by ERK and induces
VEGF production in other cells. Milanini et al demonstrated a
cooperative effect of AP-2 and Sp1 to activate the VEGF
promoter. They transfected a fibroblast cell line with mutated
VEGF promoter constructs and found that only the VEGF
promoter construct with mutations in both the Sp1 and AP-2
binding sites displayed reduced promoter activation [18]. By
performing similar promoter assay experiments, we found that a
mutation in the Sp1 binding site alone was sufficient to reduce M-
CSF-induced VEGF promoter activity to basal levels. Mutation of
the AP-2 binding site within the VEGF promoter construct did
reduce luciferase levels about 20%, however, this reduction was
not statistically significant or comparable to the luciferase
production observed with the Sp1 mutant. Therefore, we do not
rule out a possible cooperative effect of Sp1 and AP-2 for VEGF
promoter activation, but in our model of M-CSF stimulation of
human monocytes, we found Sp1 to be the main transcription
factor responsible for VEGF production.
Finally, we demonstrate the ability of M-CSF to induce
angiogenesis in vivo. Using the Matrigel plug angiogenesis assay,
we showed that M-CSF recruited mononuclear phagocytes,
increased VEGF protein levels, and increased the number of
blood vessels formed within the Matrigel plug. The recruitment of
F480-positive cells was expected as M-CSF is a known
chemoattractant for monocytes/macrophages, alone or through
induction of monocyte chemoattractant protein (CCL2/MCP-1)
by monocytes [10,41]. Our observation of increased VEGF
production and angiogenesis within the M-CSF-containing plugs
confirms the ability of M-CSF to induce angiogenesis in vivo.I n
addition to inducing VEGF production from monocytes, M-CSF
is also known to stimulate the production of other pro-angiogenic
factors, such as IL-8 [38] and MMP-9 [43]. To decipher the
angiogenic molecule responsible for the blood vessel formation in
the M-CSF-containing plugs, we added a neutralizing antibody to
VEGF to the M-CSF-containing plugs. The neutralization of
VEGF within these plugs significantly reduced the angiogenesis
implicating VEGF as a necessary molecule in M-CSF-induced
angiogenesis.
In summary, we demonstrate the biochemical details of M-CSF-
induced VEGF production. We propose a pathway involving M-
endothelial cells using an anti-mouse von Willebrand factor (vWf) antibody. Brown staining represents vWf(+) cells within the plugs. Pictures were
taken using a 206 objective lens. D) Quantification of blood vessels within each plug was determined by counting the total number of vWf(+)-
stained endothelial cells that formed a complete circle (red arrows) throughout each entire plug using a 206objective lens in a blinded manner. This
data represents three plugs per group.
doi:10.1371/journal.pone.0003405.g007
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phorylation of the transcription factor Sp1, which then translo-
cates to the nucleus and binds to its specific sequence within the
VEGF promoter to drive transcription of VEGF mRNA. Previous
data on VEGF regulation has been obtained using cell lines; we
demonstrate our phenomenon in primary human monocytes,
enhancing the relevance of this observation. This manuscript
describes the pro-angiogenic potential of M-CSF as it pertains to
mononuclear phagocyte recruitment, VEGF production, and
angiogenesis in vivo. The abundance of clinical data from cancer
patients correlating high levels of M-CSF, mononuclear phago-
cytes, and VEGF with poor prognosis highlights the importance of
increasing our understanding of this paradigm. We believe studies
linking these three components may cultivate understanding and
aid in the genesis of novel therapies for numerous cancers.
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